Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Familial Cancer
Published in: Familial Cancer 2/2010

01-06-2010

Mismatch repair protein expression and colorectal cancer in Hispanics from Puerto Rico

Authors: Wilfredo E. De Jesus-Monge, Carmen Gonzalez-Keelan, Ronghua Zhao, Stanley R. Hamilton, Miguel Rodriguez-Bigas, Marcia Cruz-Correa

Published in: Familial Cancer | Issue 2/2010

Login to get access

Abstract

Colorectal cancer (CRC) is a leading cause of morbidity and mortality and alterations in mismatch repair (MMR) genes, leading to absent protein (negative) expression, are responsible for approximately 20% of CRC cases. Immunohistochemistry is a tool for prescreening of MMR protein expression in CRC but the literature on its use on Hispanics is scarce. However, Hispanics represent the second leading ethnicity in the United States (US) and CRC is a public health burden in this group. Our objectives were to determine the frequency of MMR protein-negative CRC and to evaluate its association with clinical and pathological characteristics among Hispanics from Puerto Rico, for the first time to our knowledge. A retrospective observational study of unselected CRC patients from the Puerto Rico Medical Center from 2001 to 2005 was done. MLH1 and MSH2, the most commonly altered MMR genes, protein expression was evaluated using immunohistochemistry, with microsatellite instability (MSI) and BRAF gene analyses in the absence of MLH1 protein expression. One-hundred sixty-four CRC patients were evaluated: the overall MMR protein-negative frequency was 4.3%, with 0.6% frequency of co-occurrence of MLH1-protein negative expression, MSI-high, and normal BRAF gene. MMR protein-negative expression was associated with proximal colon location (P = 0.02) and poor histological tumor differentiation (P = 0.001), but not with other characteristics. The frequency of MMR protein-negative CRC in Hispanics from Puerto Rico was lower than reported in other populations. This finding may explain the lower CRC incidence rate among US Hispanics as compared to US non-Hispanic whites and blacks.
Literature
1.
Colorectal cancer (2003) In: Steward BW, Kleihues P (ed) World cancer report. IARC Press, Lyon
2.
3.
Raut CP, Pawlik TM, Rodriguez-Bigas MA (2004) Clinicopathologic features in colorectal cancer patients with microsatellite instability. Mutat Res 568:275–282PubMed
4.
Soreide K, Janssen EA, Soiland H et al (2006) Microsatellite instability in colorectal cancer. Br J Surg 93:395–406CrossRefPubMed
5.
Wu J, Gu L, Wang H et al (1999) Mismatch repair processing of carcinogen-DNA adducts triggers apoptosis. Mol Cell Biol 19:8292–8301PubMed
6.
Hickman MJ, Samson LD (1999) Role of DNA mismatch repair and p53 in signaling induction of apoptosis by alkylating agents. Proc Natl Acad Sci USA 96:10764–10769CrossRefPubMed
7.
Koessler T, Azzato EM, Perkins B et al (2009) Common germline variation in mismatch repair genes and survival after a diagnosis of colorectal cancer. Int J Cancer 124:1887–1891CrossRefPubMed
8.
Wijnen JT, Brohet RM, van Eijk R et al (2009) Chromosome 8q23.3 and 11q23.1 variants modify colorectal cancer risk in Lynch syndrome. Gastroenterology 136:131–137CrossRefPubMed
9.
Lynch HT, Smyrk T (1996) Hereditary nonpolyposis colorectal cancer (Lynch syndrome). An updated review. Cancer 78:1149–1167CrossRefPubMed
10.
Boland CR, Koi M, Chang DK et al (2008) The biochemical basis of microsatellite instability and abnormal immunohistochemistry and clinical behavior in Lynch syndrome: from bench to bedside. Fam Cancer 7:41–52CrossRefPubMed
11.
Raevaara TE, Korhonen MK, Lohi H et al (2005) Functional significance and clinical phenotype of nontruncating mismatch repair variants of MLH1. Gastroenterology 129:537–549PubMed
12.
Hampel H, Stephens JA, Pukkala E et al (2005) Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: later age of onset. Gastroenterology 129:415–421PubMed
13.
Shin YK, Heo SC, Shin JH et al (2004) Germline mutations in MLH1, MSH2 and MSH6 in Korean hereditary non-polyposis colorectal cancer families. Hum Mutat 24:351CrossRefPubMed
14.
Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives (2009) Genet Med 11:35–41
15.
Lynch HT, Boland CR, Rodriguez-Bigas MA et al (2007) Who should be sent for genetic testing in hereditary colorectal cancer syndromes? J Clin Oncol 25:3534–3542CrossRefPubMed
16.
Lynch HT, Boland CR, Gong G et al (2006) Phenotypic and genotypic heterogeneity in the Lynch syndrome: diagnostic, surveillance and management implications. Eur J Hum Genet 14:390–402CrossRefPubMed
17.
Ricciardiello L, Boland CR (2005) Lynch syndrome (hereditary non-polyposis colorectal cancer): current concepts and approaches to management. Curr Gastroenterol Rep 7:412–420CrossRefPubMed
18.
De Jong AE, Morreau H, Van Puijenbroek M et al (2004) The role of mismatch repair gene defects in the development of adenomas in patients with HNPCC. Gastroenterology 126:42–48CrossRefPubMed
19.
Soreide K (2007) Molecular testing for microsatellite instability and DNA mismatch repair defects in hereditary and sporadic colorectal cancers—ready for prime time? Tumour Biol 28:290–300CrossRefPubMed
20.
Chung DC, Rustgi AK (2003) The hereditary nonpolyposis colorectal cancer syndrome: genetics and clinical implications. Ann Intern Med 138:560–570PubMed
21.
Rouleau E, Lefol C, Bourdon V et al (2009) Quantitative PCR high-resolution melting (qPCR-HRM) curve analysis, a new approach to simultaneously screen point mutations and large rearrangements: application to MLH1 germline mutations in Lynch syndrome. Hum Mutat 30:867–875CrossRefPubMed
22.
Lindor NM, Burgart LJ, Leontovich O et al (2002) Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. J Clin Oncol 20:1043–1048CrossRefPubMed
23.
Hampel H, Frankel WL, Martin E et al (2005) Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med 352:1851–1860CrossRefPubMed
24.
Pawlik TM, Raut CP, Rodriguez-Bigas MA (2004) Colorectal carcinogenesis: MSI-H versus MSI-L. Dis Markers 20:199–206PubMed
25.
Cruz-Correa M, Giardiello FM (2002) Diagnosis and management of hereditary colon cancer. Gastroenterol Clin North Am 31:537–549CrossRefPubMed
26.
Bleiker EM, Menko FH, Taal BG et al (2005) Screening behavior of individuals at high risk for colorectal cancer. Gastroenterology 128:280–287CrossRefPubMed
27.
Guillem JG, Wood WC, Moley JF et al (2006) ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes. J Clin Oncol 24:4642–4660CrossRefPubMed
28.
Balmana J, Balaguer F, Castellvi-Bell S et al (2008) Comparison of predictive models, clinical criteria and molecular tumour screening for the identification of patients with Lynch syndrome in a population-based cohort of colorectal cancer patients. J Med Genet 45:557–563CrossRefPubMed
29.
Sidelnikov E, Bostick RM, Flanders WD et al (2009) MutL-Homolog 1 expression and risk of incident, sporadic colorectal adenoma: search for prospective biomarkers of risk for colorectal cancer. Cancer Epidemiol Biomarkers Prev 18:1599–1609CrossRefPubMed
30.
De Jesus-Monge WE, Gonzalez-Keelan C, Cruz-Correa M (2009) Serrated adenomas. Current Gastroenterol Rep 11:420–427CrossRef
31.
32.
Ponz de Leon M, Bertario L, Genuardi M et al (2007) Identification and classification of hereditary nonpolyposis colorectal cancer (Lynch syndrome): adapting old concepts to recent advancements. Report from the Italian Association for the Study of Hereditary Colorectal Tumors Consensus Group. Dis Colon Rectum 50:2126–2134CrossRefPubMed
33.
Lynch HT, Fusaro RM, Lynch PM (2006) Sebaceous skin lesions as clues to hereditary non-polyposis colorectal cancer. J Invest Dermatol 126:2158–2159CrossRefPubMed
34.
Shia J (2008) Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part I. The utility of immunohistochemistry. J Mol Diagn 10:293–300CrossRefPubMed
35.
de La Chapelle A (2002) Microsatellite instability phenotype of tumors: genotyping or immunohistochemistry? The jury is still out. J Clin Oncol 20:897–899PubMed
36.
Morales-Burgos A, Sanchez JL, Figueroa LD et al (2008) MSH-2 and MLH-1 protein expression in Muir Torre syndrome-related and sporadic sebaceous neoplasms. P R Health Sci J 27:322–327PubMed
37.
38.
Evans DG, Walsh S, Hill J et al (2007) Strategies for identifying hereditary nonpolyposis colon cancer. Semin Oncol 34:411–417CrossRefPubMed
39.
Hampel H, Frankel WL, Martin E et al (2008) Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J Clin Oncol 26:5783–5788CrossRefPubMed
40.
Overbeek LI, Ligtenberg MJ, Willems RW et al (2008) Interpretation of immunohistochemistry for mismatch repair proteins is only reliable in a specialized setting. Am J Surg Pathol 32:1246–1251CrossRefPubMed
41.
42.
43.
44.
45.
46.
47.
Brim H, Mokarram P, Naghibalhossaini F et al (2008) Impact of BRAF, MLH1 on the incidence of microsatellite instability high colorectal cancer in populations based study. Mol Cancer 7:68CrossRefPubMed
48.
Ashktorab H, Smoot DT, Farzanmehr H et al (2005) Clinicopathological features and microsatellite instability (MSI) in colorectal cancers from African Americans. Int J Cancer 116:914–919CrossRefPubMed
49.
Pandey V, Prabhu JS, Payal K et al (2007) Assessment of microsatellite instability in colorectal carcinoma at an Indian center. Int J Colorectal Dis 22:777–782CrossRefPubMed
50.
Ashktorab H, Brim H, Al-Riyami M et al (2008) Sporadic colon cancer: mismatch repair immunohistochemistry and microsatellite instability in Omani subjects. Dig Dis Sci 53:2723–2731CrossRefPubMed
51.
Erdamar S, Ucaryilmaz E, Demir G et al (2007) Importance of MutL homologue MLH1 and MutS homologue MSH2 expression in Turkish patients with sporadic colorectal cancer. World J Gastroenterol 13:4437–4444PubMed
52.
Jin HY, Liu X, Lin VK et al (2008) Detection of mismatch repair gene germline mutation carrier among Chinese population with colorectal cancer. BMC Cancer 8:44CrossRefPubMed
53.
Jensen LH, Lindebjerg J, Byriel L et al (2008) Strategy in clinical practice for classification of unselected colorectal tumours based on mismatch repair deficiency. Colorectal Dis 10:490–497CrossRefPubMed
54.
Boardman LA, Lanier AP, French AJ et al (2007) Frequency of defective DNA mismatch repair in colorectal cancer among the Alaska Native people. Cancer Epidemiol Biomarkers Prev 16:2344–2350CrossRefPubMed
55.
Wright CL, Stewart ID (2003) Histopathology and mismatch repair status of 458 consecutive colorectal carcinomas. Am J Surg Pathol 27:1393–1406CrossRefPubMed
56.
Coggins RP, Cawkwell L, Bell SM et al (2005) Association between family history and mismatch repair in colorectal cancer. Gut 54:636–642CrossRefPubMed
57.
Xicola RM, Llor X, Pons E et al (2007) Performance of different microsatellite marker panels for detection of mismatch repair-deficient colorectal tumors. J Natl Cancer Inst 99:244–252CrossRefPubMed
58.
Piñol V, Castells A, Andreu M et al (2005) Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer. JAMA 293:1986–1994CrossRefPubMed
59.
Terdiman JP, Gum JR Jr, Conrad PG et al (2001) Efficient detection of hereditary nonpolyposis colorectal cancer gene carriers by screening for tumor microsatellite instability before germline genetic testing. Gastroenterology 120:21–30CrossRefPubMed
60.
Christensen M, Katballe N, Wikman F et al (2002) Antibody-based screening for hereditary nonpolyposis colorectal carcinoma compared with microsatellite analysis and sequencing. Cancer 95:2422–2430CrossRefPubMed
61.
Wahlberg SS, Schmeits J, Thomas G et al (2002) Evaluation of microsatellite instability and immunohistochemistry for the prediction of germ-line MSH2 and MLH1 mutations in hereditary nonpolyposis colon cancer families. Cancer Res 62:3485–3492PubMed
62.
Park JG, Vasen HF, Park YJ et al (2002) Suspected HNPCC and Amsterdam criteria II: evaluation of mutation detection rate, an international collaborative study. Int J Colorectal Dis 17:109–114CrossRefPubMed
63.
Hitchins M, Williams R, Cheong K et al (2005) MLH1 germline epimutations as a factor in hereditary nonpolyposis colorectal cancer. Gastroenterology 129:1392–1399CrossRefPubMed
64.
Bermejo JL, Eng C, Hemminki K (2005) Cancer characteristics in Swedish families fulfilling criteria for hereditary nonpolyposis colorectal cancer. Gastroenterology 129:1889–1899CrossRefPubMed
65.
Woerner SM, Kloor M, Mueller A et al (2005) Microsatellite instability of selective target genes in HNPCC-associated colon adenomas. Oncogene 24:2525–2535CrossRefPubMed
66.
Plaschke J, Engel C, Kruger S et al (2004) Lower incidence of colorectal cancer and later age of disease onset in 27 families with pathogenic MSH6 germline mutations compared with families with MLH1 or MSH2 mutations: the German Hereditary Nonpolyposis Colorectal Cancer Consortium. J Clin Oncol 22:4486–4494CrossRefPubMed
67.
Lim SB, Jeong SY, Lee MR et al (2004) Prognostic significance of microsatellite instability in sporadic colorectal cancer. Int J Colorectal Dis 19:533–537CrossRefPubMed
68.
Cruz-Correa M, Giardiello FM (2003) Familial adenomatous polyposis. Gastrointest Endosc 58:885–894CrossRefPubMed
69.
70.
Rozen P, Macrae F (2006) Familial adenomatous polyposis: the practical applications of clinical and molecular screening. Fam Cancer 5:227–235CrossRefPubMed
71.
72.
Umar A, Boland CR, Terdiman JP et al (2004) Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 96:261–268PubMedCrossRef
73.
Fleming ID, Cooper JS, Henson DE et al (eds) (1997) AJCC cancer staging manual, 5th edn. Lippincott-Raven, Philadelphia
74.
Soto-Salgado M, Suarez E, Calo W et al (2009) Incidence and mortality rates for colorectal cancer in Puerto Rico and among hispanics, non-hispanic whites, and non-hispanic blacks in the United States, 1998–2002. Cancer 115:3016–3023CrossRefPubMed
75.
Jover R, Zapater P, Castells A et al (2009) The efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair status. Eur J Cancer 45:365–373CrossRefPubMed
76.
Carethers JM, Smith EJ, Behling CA et al (2004) Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer. Gastroenterology 126:394–401CrossRefPubMed
77.
Ribic CM, Sargent DJ, Moore MJ et al (2003) Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 349:247–257CrossRefPubMed
78.
Bertagnolli MM, Niedzwiecki D, Compton CC et al (2009) Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: cancer and leukemia group B protocol 89803. J Clin Oncol 27:1814–1821CrossRefPubMed
79.
Grover S, Syngal S (2009) Genetic testing in gastroenterology: Lynch syndrome. Best Pract Res Clin Gastroenterol 23:185–196CrossRefPubMed
80.
Beiner ME, Rosen B, Fyles A et al (2006) Endometrial cancer risk is associated with variants of the mismatch repair genes MLH1 and MSH2. Cancer Epidemiol Biomarkers Prev 15:1636–1640CrossRefPubMed
81.
Yoon SN, Ku JL, Shin YK et al (2008) Hereditary nonpolyposis colorectal cancer in endometrial cancer patients. Int J Cancer 122:1077–1081CrossRefPubMed
82.
Park JG, Kim DW, Hong CW et al (2006) Germ line mutations of mismatch repair genes in hereditary nonpolyposis colorectal cancer patients with small bowel cancer: International Society for Gastrointestinal Hereditary Tumours Collaborative Study. Clin Cancer Res 12:3389–3393CrossRefPubMed
83.
Scaife CL, Rodriguez-Bigas MA (2003) Lynch syndrome: implications for the surgeon. Clin Colorectal Cancer 3:92–98CrossRefPubMed
84.
85.
Watson P, Lynch HT (2001) Cancer risk in mismatch repair gene mutation carriers. Fam Cancer 1:57–60CrossRefPubMed
86.
Manchanda R, Menon U, Michaelson-Cohen R et al (2009) Hereditary non-polyposis colorectal cancer or Lynch syndrome: the gynaecological perspective. Curr Opin Obstet Gynecol 21:31–38CrossRefPubMed
87.
Brown GJ, St John DJ, Macrae FA et al (2001) Cancer risk in young women at risk of hereditary nonpolyposis colorectal cancer: implications for gynecologic surveillance. Gynecol Oncol 80:346–349CrossRefPubMed
88.
Schmeler KM, Lu KH (2008) Gynecologic cancers associated with Lynch syndrome/HNPCC. Clin Transl Oncol 10:313–317CrossRefPubMed
89.
Dionigi G, Bianchi V, Villa F et al (2007) Differences between familial and sporadic forms of colorectal cancer with DNA microsatellite instability. Surg Oncol 16:S37–S42CrossRefPubMed
90.
Aaltonen LA, Peltomaki P, Mecklin JP et al (1994) Replication errors in benign and malignant tumors from hereditary nonpolyposis colorectal cancer patients. Cancer Res 54:1645–1648PubMed
91.
Herman JG, Umar A, Polyak K et al (1998) Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci U S A 95:6870–6875CrossRefPubMed
92.
Kuismanen SA, Holmberg MT, Salovaara R et al (2000) Genetic and epigenetic modification of MLH1 accounts for a major share of microsatellite-unstable colorectal cancers. Am J Pathol 156:1773–1779PubMed
93.
Gryfe R, Gallinger S (2001) Microsatellite instability, mismatch repair deficiency, and colorectal cancer. Surgery 130:17–20CrossRefPubMed
94.
Lothe RA, Peltomaki P, Meling GI et al (1993) Genomic instability in colorectal cancer: relationship to clinicopathological variables and family history. Cancer Res 53:5849–5852PubMed
95.
O’Brien MJ (2007) Hyperplastic and serrated polyps of the colorectum. Gastroenterol Clin North Am 36:947–968 viiiCrossRefPubMed
96.
Esteller M, Fraga MF, Guo M et al (2001) DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis. Hum Mol Genet 10:3001–3007CrossRefPubMed
97.
Chirieac LR, Chen L, Catalano PJ et al (2005) Phenotype of microsatellite-stable colorectal carcinomas with CpG island methylation. Am J Surg Pathol 29:429–436CrossRefPubMed
98.
van Rijnsoever M, Grieu F, Elsaleh H et al (2002) Characterisation of colorectal cancers showing hypermethylation at multiple CpG islands. Gut 51:797–802CrossRefPubMed
99.
Kambara T, Simms LA, Whitehall VL et al (2004) BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum. Gut 53:1137–1144CrossRefPubMed
100.
Al-Kuraya KS, Bavi PP, Ezzat AA et al (2006) Colorectal carcinoma from Saudi Arabia. Analysis of MLH-1, MSH-2 and p53 genes by immunohistochemistry and tissue microarray analysis. Saudi Med J 27:323–328PubMed
101.
Samowitz WS, Curtin K, Ma KN et al (2001) Microsatellite instability in sporadic colon cancer is associated with an improved prognosis at the population level. Cancer Epidemiol Biomarkers Prev 10:917–923PubMed
102.
Chen JR, Chiang JM, Changchien CR et al (2008) Mismatch repair protein expression in Amsterdam II criteria-positive patients in Taiwan. Br J Surg 95:102–110CrossRefPubMed
103.
Gryfe R, Kim H, Hsieh ET et al (2000) Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med 342:69–77CrossRefPubMed
104.
Mecklin JP, Jarvinen HJ (1986) Clinical features of colorectal carcinoma in cancer family syndrome. Dis Colon Rectum 29:160–164CrossRefPubMed
105.
Watson N, Grieu F, Morris M et al (2007) Heterogeneous staining for mismatch repair proteins during population-based prescreening for hereditary nonpolyposis colorectal cancer. J Mol Diagn 9:472–478CrossRefPubMed
Metadata
Title
Mismatch repair protein expression and colorectal cancer in Hispanics from Puerto Rico
Authors
Wilfredo E. De Jesus-Monge
Carmen Gonzalez-Keelan
Ronghua Zhao
Stanley R. Hamilton
Miguel Rodriguez-Bigas
Marcia Cruz-Correa
Publication date
01-06-2010
Publisher
Springer Netherlands
Published in
Familial Cancer / Issue 2/2010
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-009-9310-4

Other articles of this Issue 2/2010

Familial Cancer 2/2010 Go to the issue

OriginalPaper

Female BRCA mutation carriers with a preference for prophylactic mastectomy are more likely to participate an educational-support group and to proceed with the preferred intervention within 2 years

BriefCommunication

A PALB2 germline mutation associated with hereditary breast cancer in Italy

BriefCommunication

Biallelic MYH germline mutations as cause of Muir-Torre syndrome

OriginalPaper

An Ashkenazi founder mutation in the MSH6 gene leading to HNPCC

OriginalPaper

Outcomes of nasopharyngeal carcinoma screening for high risk family members in Hong Kong

OriginalPaper

Hereditary leiomyomatosis and renal cell carcinoma: very early diagnosis of renal cancer in a paediatric patient
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits